Home Publications Research Grants Inventions & Patents Awards Additional Research Activities Faculties & Institutions Research Areas

Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - protocol for a systematic review

Kunath F, Spek A, Jensen K, Zengerling F, Schmidt S (2015)

---

Publication Type: Journal article

Publication year: 2015

Journal

Book Volume: 4

Pages Range: 182

DOI: 10.1186/s13643-015-0167-3

Abstract

Testicular cancer is primarily treated with the surgical removal of the affected testis. About 50% of testicular cancer patients present with a stage I seminoma. If no chemo- or radiotherapy as adjuvant treatment is initiated after orchiectomy, 15-20% of these patients will develop metastases. Although adjuvant treatment is effective in reducing the relapse risk, there is rising concern about overtreatment of these patients. Prognostic factors at primary diagnosis might have the potential to identify patients at higher risk of tumor relapse, allowing to guide individual therapy and to avoid overtreatment. Therefore, we aim to synthesize the available evidence on tumor or patient characteristics as possible prognostic factors for cancer recurrence in patients with clinical stage I seminoma.We will conduct a broad systematic review to analyze what prognostic factors predict cancer recurrence in patients with a first time diagnosis of clinical stage I seminoma, who received no adjuvant chemo- or radiotherapy after orchiectomy. The literature search will comprise MEDLINE, Web of Science, the Cochrane Central Register of Controlled Trials (CENTRAL), and the conference proceedings of the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), and European Urologic Association (EAU) Annual Meetings. Prospective and retrospective longitudinal studies reporting on prognostic factors for cancer recurrence will be considered. We will consider the wealth of any candidate clinical or pathological prognostic factor reported in the literature. Our outcome of interest will be tumor recurrence at a minimum of 2 years follow-up. Study screening, data extraction, and quality assessment will be done by two reviewers independently. Hazard ratios will be used to measure the relationship between the potential prognostic factor and tumor recurrence. Meta-analyses will be conducted with sufficiently homogeneous studies and separately with respect to study design, by using the random-effects generic inverse variance model.Limitations and strengths will be discussed in our review, and the results will be put into context with other studies in this field. Our results will help to guide evidence-based decision-making on patients with clinical stage I seminoma, allowing a better adjustment of therapies with regard to the individual patient's risk. Our findings will furthermore help to formulate recommendations for future research.PROSPERO CRD42014009434.

Authors with CRIS profile

Additional Organisation(s)

Involved external institutions

How to cite

APA:

Kunath, F., Spek, A., Jensen, K., Zengerling, F., & Schmidt, S. (2015). Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - protocol for a systematic review. Systematic Reviews, 4, 182. https://dx.doi.org/10.1186/s13643-015-0167-3

MLA:

Kunath, Frank, et al. "Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance - protocol for a systematic review." Systematic Reviews 4 (2015): 182.

BibTeX: Download